Method of inhibiting clostridium difficile by administration of oritavancin
View Patent ↗Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
1. A method of treating a C. difficile infection in a subject, comprising administering a therapeutically effective amount of a glycopeptide antibiotic to a subject having a C. difficile infection, thereby treating a C. difficile infection in a subject, wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof, and wherein the C. difficile infection comprises C. difficile spores or a mixture of C. difficile spores and C. difficile in vegetative form.
2. A method of treating a C. difficile infection in a subject, comprising administering a therapeutically effective amount of a glycopeptide antibiotic to a subject having a C. difficile infection, wherein said treatment inhibits C. difficile sporulation, thereby treating a C. difficile infection in a subject, wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof, and wherein the C. difficile infection comprises C. difficile spores or a mixture of C. difficile spores and C. difficile in vegetative form.
3. The method of claim 1 , wherein said treatment inhibits outgrowth of a C. difficile spore, inhibits growth of a vegetative form of C. difficile , or inhibits C. difficile sporulation.
4. The method of claim 1 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
5. The method of claim 1 , wherein said administering is via intravenous administration or oral administration.
6. The method of claim 1 , wherein the therapeutically effective amount of the glycopeptide antibiotic is between about 5 and 30 mg/kg body weight.
7. The method of claim 1 , wherein said administering is BID for four days.
8. The method of claim 2 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
9. The method of claim 2 , wherein said administering is via intravenous administration or oral administration.
10. The method of claim 2 , wherein the therapeutically effective amount of the glycopeptide antibiotic is between about 5 and 30 mg/kg body weight.
11. The method of claim 2 , wherein said administering is BID for four days.